Pancreatic cancer trials in Germany

In Germany 53 Also abroad 1095

53 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Berlin, Düsseldorf, Freiburg im Breisgau, München, Würzburg
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Where
Hamburg, Heilbronn, Muenchen, Munich, Riesa
Age
18 years and over
People
570 worldwide
Run by
Immuneering Corporation
See details and how to joinNCT07562152 · EU 2026-525617-31-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Essen
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 3Taking people
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Where
Aachen, Bad Saarow, Berlin, Bochum, Dresden, Duesseldorf, Frankfurt am Main, Hamburg, Hanover, Leipzig, Magdeburg, Mainz, Mannheim, Muenster, Munich, Regensburg, Saarbruecken, Ulm, Wuerzburg
Age
18 years and over
People
614 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07409272 · EU 2025-523684-38-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
Phase 3Taking people
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Where
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Göttingen, Halle, Hamburg, Leipzig, München, Munich, Nuremberg, Ulm
Age
18 years and over
People
588 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07522073
No phaseTaking people
Pancreatic Cancer Early Detection Consortium
Where
Essen
Age
18 years to 90 years
People
20,000 worldwide
Run by
Arbor Research Collaborative for Health
See details and how to joinNCT04970056
Phase 1/2Taking people
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Where
Bonn, Ulm
Age
18 years and over
People
220 worldwide
Run by
Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Where
Berlin, Frankfurt am Main, Heidelberg, Luebeck, Munich, Ulm
Age
18 years and over
People
500 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT07252232 · EU 2025-523495-23-00
Phase 3Taking people
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
Where
Aachen, Augsburg, Berlin, Bochum, Bonn, Cologne, Deggendorf, Dresden, Erlangen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Halle Saale, Hamburg, Hanover, Heidelberg, Homburg, Jena, Kiel, Leipzig, Luebeck, Mainz, Mannheim, Marburg, Munich, Paderborn, Regensburg, Rostock, Saarbruecken, Ulm, Winnenden, Wuerzburg
Age
18 years and over
People
414 worldwide
Run by
Universitaetsklinikum Heidelberg AöR
See details and how to joinNCT05314998 · EU 2024-514682-19-00
Phase 3Not yet taking people in Germany
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Where
Berlin, Bochum, Dresden, Frankfurt am Main, Hamburg, Munich, Ulm
Age
18 years and over
People
233 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2025-524969-24-00 · EU 2025-524969-24-00
Phase 1/2Taking people
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Where
Bochum, Düsseldorf, Frankfurt am Main, Lübeck, München
Age
18 years and over
People
346 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06885034
Phase 2/3Not yet taking people in Germany
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Where
Dresden, Essen, Hamburg, Ulm
Age
18 years and over
People
194 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-522563-15-00 · EU 2025-522563-15-00
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Bochum, München, Ulm
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 1Taking people
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Where
Berlin, Ulm, Wuerzburg
Age
18 years and over
People
300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00
Phase 2/3Taking people
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Where
Berlin, Dresden, Düsseldorf, Leipzig, München
Age
18 years and over
People
982 worldwide
Run by
Pfizer
See details and how to joinNCT06989437 · EU 2025-522093-36-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Essen
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Bayern, Berlin, Heidelberg, Mainz
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 3Taking people
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Where
Berlin, Bochum, Bonn, Dresden, Frankfurt am Main, Heidelberg, München, Tuebingen, Ulm, Wuerzburg
Age
18 years and over
People
900 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT07491445 · EU 2025-525088-34-00
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Magdeburg
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 1/2Taking people
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC)
Where
Berlin, Bochum, Dresden, Frankfurt am Main, Leipzig, Mainz
Age
18 years and over
People
26 worldwide
Run by
Merck Healthcare KGaA
See details and how to join2024-517819-74-00 · EU 2024-517819-74-00
Phase 2Taking people
Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer
Where
Berlin, Bochum, Mannheim, Munich, Nuremberg, Tuebingen, Ulm
Age
18 years and over
People
92
Run by
Universitaetsklinikum Ulm AöR
See details and how to join2023-510490-34-00 · EU 2023-510490-34-00